Homepage
Author:
CDT Equity Inc.
Posted Date:
May 28, 2026
CDT Equity Inc. Announces Receipt of Nasdaq Deficiency Letter
CDT Equity Inc.
May 28, 2026
CDT Announces Canadian Patent for AZD5904 in Male Infertility
CDT Equity Inc.
May 27, 2026
CDT Notes Sarborg Filing of Substance of Matter Patent in Cystic Fibrosis Market
CDT Equity Inc.
May 7, 2026
CDT Advances AZD5904 into Global Patent Phase and Initiates Partnering Discussions
CDT Equity Inc.
May 6, 2026
CDT Expands Multi-Pathway Value Creation Strategy Across Pharma, IP and AI-Driven Discovery
CDT Equity Inc.
April 16, 2026
CDT Notes Sarborg Publication of PRISM Framework Expanding AI
CDT Equity Inc.
April 7, 2026
CDT Equity Expands Tapinarof Intellectual Property Portfolio with Two New Patent Filings
CDT Equity Inc.
March 26, 2026
CDT Equity Inc. Announces Reverse Stock Split
CDT Equity Inc.
March 25, 2026
CDT Identifies Rare Disease Opportunities Through Sarborg Signature Analysis, Advancing Out-Licensing Strategy
CDT Equity Inc.
March 23, 2026
CDT Equity Stockholders Approve All Proposals at Special Meeting, Positioning the Company for Next Phase of Growth
CDT Equity Inc.
March 18, 2026
1
2
Next
